We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-28.07%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$283M
AUM Growth
-$218M
Cap. Flow
-$9.46M
Cap. Flow %
-3.34%
Top 10 Hldgs %
86.15%
Holding
21
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$101M 35.71%
6,068,125
– –
GLUE icon
2
Monte Rosa Therapeutics
GLUE
$1.4B
$30.1M 10.61%
1,472,331
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$22.4M 7.92%
1,025,000
– –
NUVB icon
4
Nuvation Bio
NUVB
$2.2B
$21.6M 7.62%
2,541,009
– –
ELEV
5
DELISTED
Elevation Oncology
ELEV
$17.1M 6.02%
2,834,910
– –
HRMY icon
6
Harmony Biosciences
HRMY
$2.04B
$15.2M 5.35%
355,415
-237,400
-40% -$9.46M
TRML
7
DELISTED
Tourmaline Bio
TRML
$10.4M 3.68%
68,292
– –
ACRS icon
8
Aclaris Therapeutics
ACRS
$726M
$9.22M 3.25%
634,455
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$8.95M 3.16%
1,332,485
– –
SYRE icon
10
Spyre Therapeutics
SYRE
$8.54B
$8.03M 2.83%
67,646
– –
OKUR
11
OnKure Therapeutics
OKUR
$154M
$7.58M 2.67%
88,608
– –
PSTX
12
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$7.11M 2.51%
1,043,267
– –
BMEA icon
13
Biomea Fusion
BMEA
$84.6M
$5.95M 2.1%
798,757
– –
SPRB
14
Spruce Biosciences
SPRB
$118M
$5.38M 1.9%
16,073
– –
TECX
15
Tectonic Therapeutic
TECX
$529M
$3.89M 1.37%
84,148
– –
MRKR icon
16
Marker Therapeutics
MRKR
$18.8M
$2.99M 1.05%
314,286
– –
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.76M 0.97%
1,386,338
– –
ZSAN
18
DELISTED
Zosano Pharma Corporation
ZSAN
$1.28M 0.45%
77,664
– –
BCEL
19
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.18M 0.41%
387,653
– –
VIRX
20
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.05M 0.37%
288,571
– –
NBRV
21
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$114K 0.04%
7,641
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Aisling Capital Management held 21 positions worth $283M, down 43% from $501M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Aisling Capital Management withdrew a net $9.46M in Q4 2021, reducing 1 holding. Its largest reduction was Harmony Biosciences, cutting an estimated $9.46M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's biggest Q4 2021 reduction was Harmony Biosciences, cutting an estimated $9.46M.
  • Aisling Capital Management's ten largest holdings make up 86% of its $283M portfolio in Q4 2021.
  • Aisling Capital Management opened 0 new positions and closed 0 in Q4 2021.
  • Aisling Capital Management's portfolio value fell 43% quarter-over-quarter to $283M.

Based on Aisling Capital Management's 13F filing for Q4 2021, filed 18 Feb 2022.